Andrew S.M. Dean

If you want to help create a future where: 1️⃣ people with rare diseases have faster diagnoses and better treatment options, and 2️⃣ innovators find a coordinated, sector-wide approach to get new tests and treatments to market, and help them stay there ➡️ read our latest report with Genetic Alliance UK: https://lnkd.in/e8iPr7Xi It recommends 10 actions that government, regulators, industry, academia, funders, clinicians, and patient groups can take to #ChangeTheRareFuture for those living with rare conditions.

119

At the Innovate UK Catapult Network, we're proud to support a huge range of innovative UK-based businesses — just like this powerful partnership between Cell and Gene Therapy Catapult and Plurify! 🪴🧬 Plurify, based in Cambridge, is redefining what's possible in cell and gene therapy. Its breakthrough RNA platform enables controllable and long lasting delivery of genetic cargo at bioreactor scale, with no genomic integration. Plurify’s RNA-based approach offers a cost-effective, scalable, and broadly applicable alternative to traditional cell engineering tools. This has the potential to streamline development, reduce costs, and help bring advanced therapies to patients more quickly and safely. The company was founded through a venture creation partnership between Cell and Gene Therapy Catapult and Deep Science Ventures. The two organisations are working together to develop a new technology that removes residual, unwanted cells from cell therapy products during manufacturing. This next‑generation purification platform avoids the need for traditional cell sorting or isolation. By developing and testing it in real‑world, industrial settings, the project aims to enhance product safety, reduce production costs and enable more therapies to reach the market. Learn more ➡️ https://loom.ly/1UNQfo0 #CatapultNetwork #RNAtechnology #BiotechInnovation #UKLifeSciences #CellTherapy #GeneTherapy #Biomanufacturing #AdvancedTherapies #BackingUKBusiness

160

4 Comments

We're pleased to announce a £5 million investment into Cyted Health, a leading gastrointestinal molecular diagnostics company, as part of an £32.5 million Series B funding round. The round was co-led with EQT Life Sciences and Advent Life Sciences, with continued support from existing investors Morningside and BGF. Founded by leading experts at the University of Cambridge, Cyted is pioneering the development of minimally invasive cell collection coupled with proprietary biomarker discovery to transform the detection of pre-cancerous, cancerous and inflammatory esophageal conditions. "Life sciences is an area of real opportunity for the UK. We have an abundance of high potential, IP rich companies that can become market leaders if they have the funding needed to scale. This is why life sciences is one of the eight key sectors included in the Government’s Industrial Strategy," says Leandros Kalisperas, our Chief Investment Officer. "The British Business Bank is already the most active investor in UK life sciences, but the sector will continue to be a priority for our investment to ensure companies like Cyted can grow and fulfil their potential."

136

1 Comment

'We need to move with the times' - Matthew Durdy, Chief Executive, Cell and Gene Therapy Catapult.   In this Pink Sheet interview, Matthew Durdy, CGT Catapult, discusses how recent changes in UK drug regulations could impact the #cell and #gene therapy industry, and how the Medicines and Healthcare products Regulatory Agency (MHRA)'s new reforms in decentralised manufacturing are a positive signal for the UK's #CellTherapy ecosystem.   Read the interview: https://lnkd.in/eK4AR8BG   #ATMPs #AdvancedTherapies Citeline

47

3 Comments

📢 Applications are now open for Accelerating FemTech: Evaluate, an Innovate UK Biomedical Catalyst Accelerator. This new 10-week programme offers tailored support to UK companies developing women’s health technologies at technology readiness level (TRL) 4+, with potential to address key challenges and conditions that affect women differently or disproportionally. Building on our work supporting early-stage innovations for women’s health, this hybrid programme is delivered with national partners to help companies grow, connect with the right people and plan testing of solutions in real-world healthcare settings, including cost-effectiveness. Participants will benefit from tailored business coaching, expert-led workshops, mentoring and targeted networking opportunities, as well as the ability to apply for a closed call funding opportunity from Innovate UK Biomedical Catalyst in Spring 2026. 👉 Applications for this Innovate UK Biomedical Catalyst funded accelerator are open until 11:59pm on 28 September: https://buff.ly/43dGmjV #BiomedicalCatalyst #FemTech #AcceleratingFemTechEvaluate

61

3 Comments

“We designed this panel to maximize clinical relevance and sequencing efficiency.” Dr. David Gokhale, Principal Clinical Scientist, St Mary’s Hospital The SureSelect Clinical Focused Exome is built on the Genomics England PanelApp and includes: • 5,629 clinically relevant genes • CNV detection and non-coding pathogenic regions • Optimized for low-input and FFPE samples • Fully automated NGS library prep with Magnis NGS prep system Learn more: https://lnkd.in/dW2X4yQD #Magnis #NGSautomation #NGS

80

📢 The UK just committed £2 billion to supercharge life sciences. It’s ambitious, bold and exactly what the sector needs. The Life Sciences Sector Plan sets out a roadmap to make the UK the #1 life sciences economy in Europe by 2030. But behind every investment, every trial, every tech breakthrough, there’s a team. And right now? That talent is the missing piece. The companies building the future of AI-powered diagnostics, genomics-enabled prevention, and decentralised clinical trials all have one thing in common: they need the right people, fast. That’s where Hlx comes in. If you're growing in life sciences or medtech, our talent strategies are built to match the pace of innovation. 👀 Swipe through to see what the plan covers — and how we can help you deliver it. #LifeSciences #MedTech #Biotech #UKLifeSciences #HealthTech #ClinicalTrials #Genomics #DigitalHealth #Innovation #HLX #NHSInnovation #R&D #TechBio #HealthcareTransformation #HiringForImpact

25

1 Comment

In a partnership between M42’s Danat Al Emarat and UK’s ProFaM, women can now extend their fertility or delay menopause using an innovative technique known as Ovarian Tissue Cryopreservation (OTC). This technology empowers women to take control of their reproductive health and reflects M42's commitment to shifting from traditional to reactive, proactive, and personalized healthcare. Learn more about this innovative technology through https://loom.ly/wL2mDI4 or https://loom.ly/faGD0qo. #M42 #CNN

47

2 Comments

🏁 Accelerator applications open! 👉 The Innovate UK Biomedical Catalyst Accelerator Future Medicines is now open for applications! We are one of the partners on this programme led by LYVA Labs and Innovate UK, supporting UK early-stage companies (TRL2-4) working on transformative innovations in future medicines, with radiopharmaceuticals identified as a priority area. Over six months, participants will gain access to: ▶️ Expertise in drug discovery, development, and regulation ▶️ Market research, commercial strategy & investor readiness support ▶️ Fully funded technical roadmap development ▶️ Access to sector experts, facilities & peer-to-peer networks ▶️ Face-to-face peer and investor event Applications are open 1 - 26 September 2025. Learn more: https://hubs.ly/Q03Gky7Z0 Apply here: https://hubs.ly/Q03Gkz8x0 This Accelerator is funded by Innovate UK Biomedical Catalyst. Innovate UK is creating a better future by inspiring, involving and investing in businesses developing life-changing innovations. #BiomedicalCatalyst

26

1 Comment

Earlier this month, BMS’s Chris Boerner, Guy Oliver, and Richard Robinson sat down with Warren A. Stephens, United States Ambassador to the UK, to discuss the historically challenging commercial environment facing U.S. biopharmaceutical companies in the UK. The discussion centred on enhancing bilateral collaboration, fair reward for innovation, tackling structural trade barriers, and unlocking the full potential of the UK’s life sciences ecosystem. US-UK partnerships in science have been the cornerstone of breakthroughs in medical science for decades. We hope this collaboration will continue for years to come. #BMSUK #NHS #LifeSciences #Investment #UKUSRelations #PharmaInnovation #HealthEconomy

416

3 Comments